Prevalence of multiple myeloma precursors revealed for the first time with iStopMM results
Researchers at iStopMM have for the first time described the prevalence of smoldering multiple myeloma and the findings indicate that it is present in 0.5% of people over 40. The high prevalence of smoldering multiple myeloma has implications for future treatment policies in multiple myeloma because people with this precursor condition, in cases where it […]
iStopMM study changes the definition of multiple myeloma precursor condition
Recently an interview appeared in Nordic Life Science with Thorir Long author of Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study, that was published in Blood Cancer Journal recently.
Sæmundur Rögnvaldsson MD, PhD
Sæmundur Rögnvaldsson a long-time member of the iStopMM core team defended his doctoral thesis Monoclonal gammopathy of what significance? Overcoming the methodological limitations of studying an asymptomatic precursor disorder on the 10th of October at the University of Iceland. Opponents were Dr. Angela Dispenzieri, professor at the Mayo Clinic and Dr. Lárus Steinþór Guðmundsson, associate […]
iStopMM team member receives IMS Young Investigator Award
We are proud to announce that a PhD student at the University of Iceland and a member of the iStopMM team Jón Þórir Óskarsson was awarded the IMS Young Investigator Award for Exemplary Abstract at the 19th International Myeloma Society Annual Meeting in Los Angeles for the abstract: Detection of Abnormal Plasma Cells by Multiparameter Flow Cytometry in […]
Major grant from the European Research Council (ERC) for further research on multiple myeloma
Sigurdur Yngvi Kristinsson professor of hematology at the University of Iceland Faculty of Medicine, specialist at Landspitali University Hospital and iStopMM´s principal investigator has been awarded a grant of EUR 2 million, the equivalent of around ISK 290 million, from the European Research Council (ERC) in order to focus on smoldering myeloma in the project […]
Multiple Myeloma Hub‘s summary of the iStopMM key talks and posters at ASH 2021
The Multiple Myelome Hub has provided a good summary of the key talks and posters from the iStopMM team at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition on their website.
Dr. Kristinsson receives a large project grant from the Icelandic Centre for Research for the next three years
Sigurður Yngvi Kristinsson, principal investigator of iStopMM, received a large project grant from the Icelandic Centre for Research (RANNIS) for the next three years for the project “Screening for Waldenström macroglobulinemia (WM) and its precursors in an entire nation.” The grant provides a unique opportunity to further investigate the data that has been collected in iStopMM, […]
High prevalence of smoldering myeloma observed in nationwide screening study
In an article in CancerTherapyAdvisor.com the iStopMM study and it‘s results are covered. Results from the study were presented at the 2021 American Society of Hematology (ASH) Annual Meeting in december. Sigrun Thorsteinsdottir, MD, PhD of The University of Iceland from the iStopMM research team says: “These results underline the necessity for improved risk stratification […]
Icelandic healthcare registries have a very high accuracy
Many of the planned studies from the iStopMM project use data on disease diagnoses in the Icelandic healthcare registries. In this paper published in the Scandinavian Journal of Public Health, the accuracy of these diagnoses was assessed and was estimated to be 98.5%, confirming the validity and accuracy of these registries for future studies. The […]
ASH 2021 packed with practice-changing hematologic cancer data
In an article in OncLive experts specializing in multiple myeloma mention what they believe to be the top studies presented at the 2021 ASH annual meeting and how their findings have the potential to change clinical practice.